195 related articles for article (PubMed ID: 33067351)
21. Neurofibromatosis type 2 (NF2): a clinical and molecular review.
Evans DG
Orphanet J Rare Dis; 2009 Jun; 4():16. PubMed ID: 19545378
[TBL] [Abstract][Full Text] [Related]
22. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.
Kluwe L; Mautner V; Heinrich B; Dezube R; Jacoby LB; Friedrich RE; MacCollin M
J Med Genet; 2003 Feb; 40(2):109-14. PubMed ID: 12566519
[TBL] [Abstract][Full Text] [Related]
23. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
24. Current progress in genomics and targeted therapies for neurofibromatosis type 2.
Hiruta R; Saito K; Bakhit M; Fujii M
Fukushima J Med Sci; 2023 Aug; 69(2):95-103. PubMed ID: 37468280
[TBL] [Abstract][Full Text] [Related]
25. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
26. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?
Evans DG; Ramsden RT; Gokhale C; Bowers N; Huson SM; Wallace A
Clin Genet; 2007 Apr; 71(4):354-8. PubMed ID: 17470137
[TBL] [Abstract][Full Text] [Related]
27. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.
Wallace AJ; Watson CJ; Oward E; Evans DG; Elles RG
Genet Test; 2004; 8(4):368-80. PubMed ID: 15684865
[TBL] [Abstract][Full Text] [Related]
28. [Type 2 neurofibromatosis: intergenerational differences in genetic and clinical expression].
Drouet A; Le Moigne F; Salamé D; Quesnel L; Motolese C; des Portes V; Guilloton L; Pinson S
Arch Pediatr; 2014 Nov; 21(11):1233-40. PubMed ID: 25439059
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
30. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.
Bourn D; Carter SA; Evans DG; Goodship J; Coakham H; Strachan T
Am J Hum Genet; 1994 Jul; 55(1):69-73. PubMed ID: 8023853
[TBL] [Abstract][Full Text] [Related]
31. Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component.
Catasús N; Garcia B; Galván-Femenía I; Plana A; Negro A; Rosas I; Ros A; Amilibia E; Becerra JL; Hostalot C; Rocaribas F; Bielsa I; Lazaro Garcia C; de Cid R; Serra E; Blanco I; Castellanos E;
J Med Genet; 2022 Jul; 59(7):678-686. PubMed ID: 34348961
[TBL] [Abstract][Full Text] [Related]
32. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
33. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
34. Determination of the mutant allele frequency in patients with neurofibromatosis type 2 and somatic mosaicism by means of deep sequencing.
Spyra M; Otto B; Schön G; Kehrer-Sawatzki H; Mautner VF
Genes Chromosomes Cancer; 2015 Aug; 54(8):482-488. PubMed ID: 26031996
[TBL] [Abstract][Full Text] [Related]
35. Neurofibromatosis type 2 in the elderly population: clinical and molecular features.
Goutagny S; Bah AB; Parfait B; Sterkers O; Kalamarides M
Am J Med Genet A; 2013 Apr; 161A(4):667-70. PubMed ID: 23322716
[TBL] [Abstract][Full Text] [Related]
36. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II].
Evans DG
Genet Med; 2009 Sep; 11(9):599-610. PubMed ID: 19652604
[TBL] [Abstract][Full Text] [Related]
37. Ocular alterations, molecular findings, and three novel pathological mutations in a series of NF2 patients.
Waisberg V; Rodrigues LOC; Nehemy MB; Bastos-Rodrigues L; de Miranda DM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1453-1458. PubMed ID: 31089872
[TBL] [Abstract][Full Text] [Related]
38. A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma.
Chu YW; Cheuk DK; Chung BH; Bowers NL; Ha SY; Chiang AK; Chan GC
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25406210
[TBL] [Abstract][Full Text] [Related]
39. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
[TBL] [Abstract][Full Text] [Related]
40. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.
Evans DG; Wallace AJ; Wu CL; Trueman L; Ramsden RT; Strachan T
Am J Hum Genet; 1998 Sep; 63(3):727-36. PubMed ID: 9718334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
